Everyone, my name is Maury Raycroft, and I am one of the biotech analysts at Jefferies. I would like to welcome Ameet Mallik, the CEO of ADC Therapeutics. Thanks so much for joining us today, Ameet. Maybe for those who are new to the story, if you can give a one-minute intro to ADC.
Sure. Thanks for the opportunity too. Great to be here with you. ADC Therapeutics is a commercial-stage antibody-drug conjugate company. We have an approved product in ZYNLONTA, which is a CD19-directed ADC. We already have an approved indication in third-line plus DLBCL, where we have a profile of rapid, deep, and durable responses with a very manageable safety profile. It is already being used in the third-line plus setting, and we are looking to expand both into earlier lines in combination in second-line plus DLBCL, as well as into indolent lymphomas. We have really excellent data in both those settings.
Got it. Yeah, it is a great intro and very efficient. Let us start with your LOTIS-7 data. You have an oral presentation coming up at ASH on December 13th. Maybe to level set the audience, can you walk through the data that you presented in the ASH 2026 abstract, and what are you seeing on CR rate and early durability, and how does the efficacy and safety profile compare with what current treatment options are in second-line DLBCL?
Sure, yeah. LOTIS-7 is our study looking at the combination of our approved ADC, ZYNLONTA, with the approved bispecific from Roche, glofitamab. Importantly, when you combine these very potent single-agent drugs, we get really outstanding efficacy and safety results. In the 97 efficacy-evaluable patients, we were able to demonstrate in the study an 89% overall response rate and 75% complete response rate. Also importantly, beyond the excellent depth in this setting, the durability also looks very good. The duration of CRs was 79% at 12 months. When you look at other bispecific combination studies in that second-line plus setting, CR rates typically range between 51% and 61%, and the durability of CRs typically ranges between 63% and 75%. We think we really have a differentiated profile with this study. Importantly, also, the safety profile was manageable.
The types of AEs that we saw were very consistent with the known profiles of ZYNLONTA and glofitamab. We are excited now to move forward towards pursuing a phase III study with this combination.
Got it. With the CR rate, it is much higher, pretty impressive CR rate there. I guess, what do you need to have to just offset the potential for monitoring or other complexity with the combination therapy? Could those requirements ultimately limit use at academic centers, or to academic centers?
Yeah, I do not think so, because if you already look at bispecifics today, they are not only being used in the academic centers, and they are not as restricted as, say, a CAR T, where you have to be in an accredited center, and it is a subset of academic centers. Bispecifics are being used broadly across academic centers and increasingly in the community, especially in the larger community centers. I expect that that will continue to grow, because bispecifics are not only playing a role in DLBCL. There is, I think, there is over a dozen approved bispecifics across different settings. I do think community oncologists and hematologists will continually to get more comfortable.
Now, one of the things with glofitamab that is in the label is when you do the step-up dosing of glofitamab, that is when you can have the signs of CRS and ICANS, and that is where hospitalization is in the label. We have been able to improve upon that profile because the way we are dosing is, you give the obinutuzumab, which is in the label of glofitamab, on day one. Then we give ZYNLONTA on day two, before the step-up dosing of glofitamab on day eight and day 15, in order to debulk the tumor, reduce the CRS rates and grades. We have been very successful. If you look at the glofitamab label on its own, the third-line plus setting, it is about a 70% CRS rate. What we saw in this study is 32%, and it was all grade 1 or 2, with one exception.
We also saw a low rate of ICANS of only 4.9%, with only grade 1 and 2. We think actually the profile we have improves upon the glofitamab study profile, in that it has lower rates and grades of CRS and ICANS. As we move forward from a regulatory strategy, one of the things we want to align with the FDA is to remove the hospitalization requirement potentially in the protocol. Roche has been able to successfully do that with their SKYGLO study, their frontline study. We're working very closely with them, and we'll work very closely with the FDA and other regulators to try to remove that hospitalization requirement. That will make it very broadly accessible.
Got it. That would be for the phase III?
For the phase III, yeah.
Yeah. On safety in your data, there were the two treatment-related grade 5 capillary leak events. You've pointed to holding or stopping ZYNLONTA earlier when edema appears. How are you thinking about constructing a dose hold framework for potential phase III?
Yeah, I think with any combination, it's all about benefit-risk. We have to have outstanding efficacy. You always want to have the best safety profile. When you look at our overall grade 5 TEAEs, the rate is about 3%. Just by way of comparison, again, when you look at other bispecific combinations, they're typically between 5% and 13%. I think we're in a reasonable range. There were three cases. One was deemed likely unrelated, which was a sepsis case, and then there were the two capillary leak syndrome cases that you mentioned. We know that edema and effusion can occur with ZYNLONTA, given the payload. That's one of the side effects. It's all about how you manage it. There's already things that are in the label, in the protocol, around using dexamethasone to pretreat, doing some dose modification.
But we're going to be more specific in the protocol for our phase III study around some of that dose modification. We have to align that with the FDA, but I think there are other measures, as we've kind of analyzed, that we can take to even further reduce. For example, upon initial signs, you could always halt or stop treatment. Patients get into a CR very quickly. I think we can get the benefit without having to build upon the edema and effusion, which can build over time with more dosing.
In other words, you wouldn't anticipate some sort of dose modification to affect a CR? Because those happen quickly, and so you anticipate that that would happen after the CR.
I mean, the majority of CRs are happening at the first disease assessment. We saw that with monotherapy. We've seen it in all of our combination studies. They happen very, very quickly. When you get to a CR, they tend to be very durable. Also remember, this is a combination treatment. Even in the rare cases where you may want to dose modify, because remember, this capillary leak syndrome is very rare. It's only 2% of cases. But in the rare cases you want to do it, you're still continuing glofitamab.
Yeah.
You may already be in a CR, and you're still continuing with the bispecific. We believe that the profile of this will be very manageable.
Got it. At ASH, the oral presentation could include about four months more of durability follow-up if the journal you're submitting to, the NCCN Compendia listing allows it. Maybe talk about that. Do you have clarity on that yet, or when are you going to know more?
Yeah. We will share updated data. So-
Okay
Breaking news for you.
Okay.
As you know, in the abstract, it was 10.4 months of follow-up. That was with a June 15th cutoff. We will have a later data with a little over more than four months more of data. That is what we plan to share in an ASH presentation. For both LOTIS-7 as well as for our ZYNLONTA in marginal zone, we are going to have updated data versus what was in the abstract in the presentations.
Okay. That is helpful. Basically, the journal said that that is okay for you guys to do that.
Yeah.
Yeah.
It makes it even better, because obviously, when you cross the 12 months, from a follow-up standpoint, that's very meaningful for physicians. We wanted to obviously share more data. We think it's only going to strengthen the case. We're excited that we're able to align that, and we're excited to be able to share more updated data in the presentation and in a publication.
Got it. Okay. Maybe talk a little bit more about what you're going to be able to show there. Are you going to have enough patients to show PFS landmarks or duration of CRs out to 18 months? How much will the additional four months provide in terms of durability versus the old cutoff?
Yeah, I think it's going to give a lot more data in terms of durability. I can't go into the specifics because we're embargoed, both by the journal and ASH, to go through specifics. I can tell you, PFS won't be mature with even four months of data. I think the data is going to be meaningful, and we will be able to share much more around durability. But I can't get into specifics until we get to the presentation.
Got it. Okay. You plan to submit the LOTIS-7 for potential NCCN Compendia listing in first quarter 2027, and you're targeting inclusion in first half of next year. How much of the second line plus share could a Compendia listing allow you to capture without a phase III, especially in academic centers? What could that mean for ZYNLONTA revenue in second half of 2027 and 2028?
Yeah. Let me just first say what is happening in the environment. Bispecifics have really, I think, reshaped the treatment landscape within DLBCL. When you look at the third line plus setting, they have over 35% share. That is in the approved indication. We know there are multiple bispecific combinations that are in Compendia in the second line setting, and they are being used. Because I think only about 20% of patients get a CAR T in that second line plus setting, and then outside of that, the treatment landscape is pretty fragmented. The bispecific-based therapies have just had the best efficacy. Physicians want to have that treatment option. What I can tell you is, if and when we get into Compendia, we will not promote off-label.
Obviously, it is going to be up to the sole discretion of the physician to decide what is in the best interest of patients. But we want to make sure that we provide the information to NCCN and other Compendia guidance, and if they deem it appropriate, for physicians to have that option.
Okay. Not saying much more on what revenue could look like.
What I can tell you is, look, if you look at the market right now, every 10 share points in second line plus is worth about $300 million. Just to kind of frame it in terms of what share points are worth, we are not giving guidance because obviously we are not going to promote-
Yeah
Off-label.
Yeah.
But I would say that's just a way to kind of understand what the market-
Conceptual, got it.
what the market size is in general. But we want to make sure that physicians have the options that they need and that we make it available. Then we, of course, are committed to a phase III study that we're aligning with the FDA.
Got it. Digging into the commercial opportunity, what proportion of second line DLBCL patients are treated at academic centers versus the community?
Today, we estimate that it is about 40% of patients treated in the academic centers in second line versus 60% in the community. That bumps to about 50/50 when you get to the third line plus setting. You get more and more referrals as patients progress to later lines. That is how we would estimate the market today.
Okay. As far as reimbursement goes, do you expect any friction with a two-drug regimen?
No. Actually, in DLBCL, the only single-agent drugs approved outside of CAR T or bispecifics in ZYNLONTA, everything from frontline on is really about combination therapy. I do not expect any resistance.
Got it. Community oncologists know ZYNLONTA from its accelerated approval use in third line plus DLBCL. CRS has been numerically lower with the combo than with glofitamab alone because of the debulking. Is the CRS profile manageable enough for community practices, or would it still require hospitalization or referral to a specialist center?
Yeah. So, as we discussed earlier, the glofitamab on its own has about a 70% CRS rate. Most of it is low grade, but there is some grade 3 and 4, and that's what led to the hospitalization requirement in the label. I would say even with that, you are seeing some use of bispecifics, especially in the more sophisticated and larger community centers. It's already happening today. But to get broader use, of course, removing that hospitalization requirement would be important. So what we've seen through our debulking strategy by giving ZYNLONTA a week before, essentially, you do the step-up dosing of glofitamab, is CRS rates that are about half. We have a 32% CRS rate versus 70% with glofitamab on its own, and it's all grade 1 and 2 with one exception of grade 3.
Based on that profile, we will discuss with the FDA the possibility of removing the hospitalization requirement in the protocol. And we're working closely with Roche on that.
Okay. And you previously planned to seek breakthrough therapy designation for LOTIS-7 in 2026, but that milestone is no longer in your guidance. Wondering if a formal request was submitted, and if not, what changed in your assessment of the opportunity?
Yeah, so we had a good initial discussion with the FDA. I think what came out of that is they're really committed to working with us on the phase III approach. We have a meeting upcoming this quarter to talk about that in more specificity around the design. So I think it was a very productive discussion with them. I think what they said is that breakthrough designation especially is typically not as appropriate for when you have two approved agents in combination. That kind of wasn't the intention of breakthrough designation. But it was a great chance for us to have an initial dialogue with them.
Got it.
I think to hear their commitment around collaborating with us on the phase III design, we will have more details to share once we have met with them.
Got it. Okay. You have the Type B meeting scheduled for this quarter. Do you expect to have a final FDA meeting minutes from that meeting by year end or early 2027? Would you wait for those minutes before disclosing the phase III design, or could you potentially provide that update sooner?
Yeah, we really look forward to this meeting, and obviously, like in any other phase III design, you are going to talk about patient population, comparator arm, endpoints, I mean, all the typical things. Typically these things do not happen all in one meeting, right? You submit it, they are going to raise some questions, and then you are going to have to go back, and it will be a little bit iterative. As we kind of finalize design, we will of course share updates with the market.
Got it. Okay. You have discussed moving toward a more active investigator choice control arm, versus using R-GemOx. How do you design the study to maximize the probability of success without introducing too much variability in the control arm?
Yeah, I think one of the issues that we've seen, and it's not just we've seen it, we've seen it in the STARGLO study and some of the EPCORE studies. I mean, when you go against R-GemOx, there tends to be a lot of censoring because investigators don't like it, and that can affect not only the PFS read, where sometimes the control arm over-reads, right? Or it can affect overall survival because that can be affected by subsequent therapy. There's a lot of issues, and you tend to have low U.S. enrollment if you don't have a comparator arm that physicians are excited about, right? So I think we want to make sure that we have a more active comparator arm. Obviously, there will be more and more options available that are either approved or in compendia, bispecific-based therapies or other combinations that are very active.
We think we'll have to align that with the FDA, but we think there are going to be some good options to do that will be attractive also for U.S. physicians, because we do want to have higher U.S. enrollment in this phase III study.
Got it. Okay. How do you think about OS for the phase III, and is there anything you can do here strategically to maximize the benefit on OS?
Yeah, overall survival is important, obviously. I mean, it's very important. It's typically a key secondary endpoint, the most important secondary endpoint, really, in any of these studies. We know that subsequent therapies affects overall survival, so it's really important in terms of how we choose the comparator arm, our arm, and how we design the study. So that is one of the key considerations, I think, in terms of the design.
Could the FDA potentially ask you to have glofitamab monotherapy in the control arm for contribution of components?
I think contribution of components is important for the FDA, I think, in any study. I think that's always important. I think there's a number of ways to do it. As you know, monotherapy is only approved for the bispecifics in the third line plus setting. For example, you've seen other studies where the contribution of components can be another CD20-based therapy with chemo versus an ADC. So there's a lot of ways in which we can address contribution of components, and I do suspect that's going to be part of the discussion with the FDA, but I think there's multiple ways that we can solve for that go beyond monotherapy.
Got it. Okay. That would have to be something in the phase III study?
I think in any phase III study, you have to consider contribution of components, because they want to really understand the treatment effect of the treatment arm versus the control arm. I think in any study, that's an important consideration.
Yeah.
Yeah.
Your runway reaches into 2029, but a phase III study would take longer. What are your latest thoughts on a potential formal partnership with Roche or Sobi?
Yeah, our cash runway basically assumes, I'd say, modest revenue growth over the next few years, coupled with an investment in the phase III study for the ZYNLONTA-glofitamab combination, as well as a phase III study for ZYNLONTA in marginal zone lymphoma. The cash runway then gets into 2029. What we haven't baked in is any partner contribution, whether they be commercial or regulatory milestones from our existing partners or any contribution, whether it be from Roche, Sobi, Tanabe, in terms of co-investing in the study. Any of those things would only further extend the runway, obviously. We try to be conservative. Until it's locked in, we don't bake any of that in. We're in discussions with all those parties right now on how we're going to execute the study and what the collaboration's going to look like. As we have more information, I'll share it.
Got it. It seems like those parties are interested as well and could potentially have motivation to help out.
Yeah, I think, look, I think this data is outstanding, right? It is the best data we have seen in second line plus DLBCL, and it is encouraging and obviously can have global impact. Where CAR T, which really has excellent efficacy data and excellent durability, the reality is the penetration of CAR T is relatively low. It is only 20% in the U.S. and oftentimes much lower in other parts of the world. Having an off-the-shelf therapy that can have really deep and durable responses in that relapsed refractory setting is important. We want to pursue a global approach, and I think our partners in general are very excited about this combination.
Got it. Are you working on a glofitamab supply agreement with Roche, and would there be anything unique on the economics there?
Yeah, so we are collaborating closely with Roche. I do not want to disclose anything other than to say I think they have been really good for us from a strategic standpoint. Operationally, they are obviously really experts in DLBCL. From a supply standpoint, they have, up to this point with the LOTIS-7 study, provided clinical supply. Again, forward-looking, we will share details once we have them.
Got it. With one or more T-cell engager likely moving into frontline DLBCL, including EPKINLY plus R-CHOP that hit stat sig on PFS, and Roche's SKYGLO with glofitamab plus Pola R-CHP, potentially reading out in 2027, how important is it to show efficacy in TCE experience or refractory patients to support the ZYNLONTA plus glofitamab combo?
Yeah, I think as bispecifics potentially move to that frontline setting, one thing to note is where they are being studied is in IPI 2 to 5 patients. It is about two-thirds of the frontline patients. It is not every patient that can qualify. While I think there is going to be, assuming they get approved, faster adoption in academic centers, it will take some time in the community where there is not as much experience with bispecifics. I think there will still be a large portion of patients that are bispecific-naive in the frontline setting. Then for those who are treated, what physicians tell us is, if a patient has a response but relapses after 12 months, they want to retreat. Retreating with a CD20-based therapy is very common within DLBCL. RITUXAN-based therapies, right, as a backbone, have been happening within DLBCL across multiple lines of therapy.
I think that same thing will happen with bispecifics. Assuming a patient had a response and relapsed, they were not actually primary refractory. I think the majority of patients, just given the data with bispecific frontline, will likely respond. I do think if you are going to get retreatment, you are not going to do a bispecific chemo, because that is what you gave frontline. You are going to want to treat with a different mechanism. I think that positions ZYNLONTA really well as a combination partner for subsequent use of bispecifics in other lines of therapy.
Got it. Would you want to include a subset of patients previously treated with the CD20 TCE in your phase III?
Yeah, already in LOTIS-7, we did not exclude prior bispecific exposure. We excluded prior glofitamab, but they could have had mosunetuzumab, epcoritamab. Similarly, in our phase III design, we do expect that there will be allowed to have prior bispecific exposure, assuming they were not primary refractory. Because obviously, if it is primary refractory, the patient is not going to benefit, right? So if they had exposure, they had a response and relapse. Of course, we have to align that with the FDA, but that would be our intention.
Got it. Okay. Would you cap that percentage, probably?
We have to work out those details with the FDA.
Yeah.
But we've had prior exposure in LOTIS-7, and I would expect that that will continue.
Yeah. Makes sense. Talk about next steps on your phase III rituximab LOTIS-5 combo on the regulatory front, and have you gotten feedback from FDA?
Yeah, importantly, the study met the primary endpoint, but of course, given the safety imbalance, the FDA expressed concerns around the benefit-safety profile. I think what I can tell you is we're exploring all options, including the phase III study with ZYNLONTA-glofitamab. I can just say that we're very committed to working with the FDA on a path forward to secure the confirmatory trial for ZYNLONTA. As we have more, these are obviously interrelated, right?
The phase III LOTIS-7 combo could potentially help?
Potentially, yeah.
Okay.
Yeah.
You'll also present data from an investigator-initiated trial with ZYNLONTA monotherapy in marginal zone lymphoma, and that'll be an oral presentation at ASH, with potential for NCCN Compendia inclusion in second half of 2027. Maybe talk about whether you plan to file for breakthrough therapy designation in marginal zone in first half of 2027, and what are next steps on the regulatory path?
Yeah, this phase II IIT, just in terms of the data, had 43 efficacy-evaluable patients. We had a 93% overall response rate, 74% complete response rate. Just to give you a sense, if you look at non-CAR T options, typically the complete response rates are below 30% in marginal zone. This is single-agent ZYNLONTA with a fixed duration of only up to six cycles. So I think it's very attractive in an indolent disease where you get such efficacy. You can get people into a complete response that's durable with a fixed duration of treatment and a manageable safety profile. When you look at marginal zone lymphoma, there's very few approvals. So CAR T is approved in third line plus, but in the second line plus setting, there's only R², and then there's zanubrutinib, the BTK inhibitor. There's not a lot of options.
Those approvals were based on 60 to 70 patients, right? There's never been a large phase III marginal zone study ever conducted. We do think that this study, which is going to go to 50 patients, may be able to form the basis. We'll have that discussion with the FDA. So we plan to have a breakthrough designation discussion with the FDA in the first half of next year and explore the option of using this study for potential accelerated approval.
Got it. Given the precedent for single-arm accelerated approvals in MZL, could the existing investigator-initiated MZL study support filing, followed by a company-sponsored confirmatory study?
That's what we're going to explore with the FDA. That's what we would hope. But that's what we have to talk about with the FDA in the first half of next year.
Okay. So maybe in closing, if you want to highlight key catalysts ahead over the next six to 12 months, including competitor readouts that investors should be focused on.
Sure. Yeah, I think from a competitor standpoint, I think probably what most people are excited about is the frontline data, right, for bispecifics. I think that's probably the most exciting competitor data that's going to be emerging potentially as soon as this ASH, right, with the epcoritamab data, and subsequently, I think, glofitamab data probably sometime next year. I think from our standpoint, we're going to have updated data. We have five oral presentations at ASH, so we have a really pretty robust as well as multiple posters. Two of those orals are the LOTIS-7 data in marginal zone. While the abstract data, I think, looks really good, we're going to have more follow-up with both of those, and I think we're going to be able to show even more robust data when we actually get to those presentations. So that's one catalyst to look forward to.
Obviously, we have regulatory discussions with the FDA, so around LOTIS-7 for the phase III of that combination. We have a discussion with the FDA later this year. We have planned to meet with the FDA in terms of breakthrough designation for ZYNLONTA in marginal zone in the first half of next year. Of course, upon publication, plan to submit both of these for NCCN Compendia inclusion, which we expect to happen next year. LOTIS-7 in the first half of next year and ZYNLONTA in marginal zone in the second half of next year. So, we think there's a lot of good catalysts coming, both in terms of data, compendia, and regulatory clarity.
Yeah, so a lot happening in the next 12 months.
Yes
For sure. Ameet, thanks so much for joining us today.
Yeah, we appreciate it. Thank you so much.